These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 880966)

  • 41. [Experimental neoplasms induced by alkylating cytostatics and alkylating antibiotics].
    Roth J
    Hippokrates; 1971 Jun; 42(2):231-3. PubMed ID: 5566032
    [No Abstract]   [Full Text] [Related]  

  • 42. The therapeutic potential of misonidazole enhancement of alkylating agent cytotoxicity.
    Hirst DG; Brown JM
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):639-42. PubMed ID: 7107389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The mechanism of tumor drug resistance].
    Kulik GI
    Vopr Onkol; 1969; 15(11):60-4. PubMed ID: 5368841
    [No Abstract]   [Full Text] [Related]  

  • 44. [The effect of antineoplastic drugs on blood and tumor water-electrolyte balance in mice and rats].
    Pashinskiĭ BG
    Vopr Onkol; 1969; 15(6):65-8. PubMed ID: 5820355
    [No Abstract]   [Full Text] [Related]  

  • 45. Site-directed chemotherapy with a drug bound to anti-idiotypic antibody to a lymphoma cell-surface IgM.
    Hurwitz E; Kashi R; Burowsky D; Arnon R; Haimovich J
    Int J Cancer; 1983 Jun; 31(6):745-8. PubMed ID: 6862683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential bioreductive alkylating agents. 3. Synthesis and antineoplastic activity of acetoxymethyl and corresponding ethyl carbamate derivatives of benzoquinones.
    Lin AJ; Shansky CW; Sartorelli AC
    J Med Chem; 1974 May; 17(5):558-61. PubMed ID: 4830263
    [No Abstract]   [Full Text] [Related]  

  • 47. Modification of alkylating agent cytotoxicity by cisplatin.
    Horsman MR; Hirst DG; Brown DM; Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1669-73. PubMed ID: 6541216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Quantitative evaluation of the efficacy of antineoplastic agents].
    Karavainova MKh
    Farmakol Toksikol; 1971; 34(5):618-21. PubMed ID: 5004886
    [No Abstract]   [Full Text] [Related]  

  • 49. [Antitumor chemotherapy. Trial and results of a new antineoplastic agent with a double mechanism of alkylating and antimetabolic action].
    Battaglia L
    Clin Ter; 1974 Dec; 71(6):573-93. PubMed ID: 4448054
    [No Abstract]   [Full Text] [Related]  

  • 50. Daunomycin--immunoglobulin conjugates, uptake and activity in vitro.
    Hurwitz E; Maron R; Arnon R; Wilchek M; Sela M
    Eur J Cancer (1965); 1978 Nov; 14(11):1213-20. PubMed ID: 738327
    [No Abstract]   [Full Text] [Related]  

  • 51. Increased therapeutic efficiency of a lipid-soluble alkylating agent incorporated in liposomes.
    Babbage JW; Berenbaum MC
    Br J Cancer; 1982 Jun; 45(6):830-4. PubMed ID: 7093119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biologic characterization of the subcutaneously implanted Lewis lung tumor.
    Mayo JG
    Cancer Chemother Rep 2; 1972 Nov; 3(1):325-30. PubMed ID: 4660735
    [No Abstract]   [Full Text] [Related]  

  • 53. [Preliminary observations on the results of treating malignant lymphoma with Lycurim].
    Polubiec A; Kolakowska-Polubiec K; Mariańska B; Perzanowska I
    Acta Haematol Pol; 1977; 8(3):213-9. PubMed ID: 200051
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo and in vitro effects of tumour specific antibodies with chlorambucil.
    Davies DA; O'Neill GJ
    Br J Cancer Suppl; 1973 Aug; 1():285-98. PubMed ID: 4548355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The effect of alkylating cytostatics on the development of secondary malignant tumors].
    Galajda P; Donner L
    Vnitr Lek; 1984 Aug; 30(8):756-63. PubMed ID: 6506498
    [No Abstract]   [Full Text] [Related]  

  • 56. Potentiation of antitumor drug action by centrophenoxine: specificity.
    Sladek NE
    J Pharmacol Exp Ther; 1977 May; 201(2):518-26. PubMed ID: 323465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of alkylating agents in acute and chronic leukemia.
    Canellos GP
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():46-7. PubMed ID: 2713560
    [No Abstract]   [Full Text] [Related]  

  • 58. Azetepa--a new alkylating agent.
    McLean JA
    Isr J Med Sci; 1965 Jul; 1(4):805-7. PubMed ID: 5323047
    [No Abstract]   [Full Text] [Related]  

  • 59. Suppression of human alpha-foetoprotein-producing hepatocellular carcinoma growth in nude mice by an anti alpha-foetoprotein antibody-daunorubicin conjugate with a poly-L-glutamic acid derivative as intermediate drug carrier.
    Tsukada Y; Ohkawa K; Hibi N
    Br J Cancer; 1985 Jul; 52(1):111-6. PubMed ID: 2410001
    [No Abstract]   [Full Text] [Related]  

  • 60. Chemosensitization at elevated temperatures.
    Chaplin DJ
    Int J Hyperthermia; 1995; 11(3):451-2; discussion 453-4. PubMed ID: 7636331
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.